Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations representing the predominant mechanisms conferring secondary ibrutinib resistance.
|
31180577 |
2020 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bruton's tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia.
|
31171644 |
2020 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These 4 agents include the Bruton tyrosine kinase inhibitor ibrutinib, the B-cell leukemia/lymphoma-2 inhibitor venetoclax, and the phosphatidylinositol-3 kinase inhibitors idelalisib and duvelisib.
|
31764124 |
2020 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is increasingly used in the treatment of chronic lymphocytic leukemia (CLL).
|
31699465 |
2020 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies.
|
31821686 |
2020 |
Chronic Lymphocytic Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients.
|
31682002 |
2020 |
Chronic Lymphocytic Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on our previous finding that a humanized monoclonal antibody against ROR1 increases the activity of Ibrutinib against CLL, which is currently undergoing evaluation in clinical trials for the treatment of B-cell lymphoid malignancies, we then provided evidence that treatment with HSP90i (17-DMAG) enhances anti-CLL activity of Ibrutinib in vitro and in vivo, by down-modulating ROR1. iTRAQ-based quantitative proteomic analysis of other HSP90 oncogenic clients in addition to ROR1, followed by GO/KEGG enrichment analysis, showed that Bruton's Tyrosine Kinase (BTK), B-lymphoid Tyrosine Kinase (BLK), Lymphocyte-specific Protein Tyrosine Kinase (LCK), or LCK/YES-Related Novel Protein Tyrosine Kinase (LYN), as HSP90 clients, were significantly involved in 11 biological processes and 6 signaling pathways.
|
31726100 |
2020 |
Chronic Lymphocytic Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Chronic activation of the Bruton's tyrosine kinase (BTK)-mediated B-cell receptor (BCR) signaling is a hallmark of many B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
|
31801949 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a Bruton's tyrosine kinase inhibitor has reformed the treatment of various B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.
|
30045682 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has substantially improved therapeutic options for chronic lymphocytic leukemia (CLL).
|
30692684 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results showed that compound <b>11g</b> displayed the best inhibitory activity on BTK with an inhibition rate of 82.76% at 100 nM and excellent anti-proliferation activity on three B-cell leukemia lines (IC<sub>50</sub> = 3.66 μM, 6.98 μM, and 5.39 μM against HL60, Raji and Ramos, respectively).
|
30881616 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ibrutinib, an oral inhibitor of the Bruton's tyrosine kinase (BTK) has proved to be remarkably efficient against treatment naïve (TN), heavily pre-treated and high-risk chronic lymphocytic leukaemia (CLL), with limited adverse events.
|
31076570 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated a next-generation phosphoinositide-3-kinase-δ inhibitor (PI3K-δi), umbralisib, plus a Bruton tyrosine kinase inhibitor (BTKi), ibrutinib, in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma.
|
30558987 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B-cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia.
|
30663221 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of BTK and p-BTK on CD5<sup>+</sup>B lymphocytes in AIHA/ES patients were higher than those in HCs and CLL patients.
|
31392938 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expert opinion: Treatment options for CLL have increased significantly with the introduction of the BTK inhibitors, PI3K inhibitors, BCL2 inhibitors, and novel anti-CD20 monoclonal antibodies.
|
30686074 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 2013, ibrutinib was approved by the FDA as the first-in-class BTK inhibitors for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), and now it is also undergoing clinical evaluation for other indications in either single or combined therapy.
|
30888232 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second-generation, enhanced-selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL) and chronic lymphocytic leukemia (CLL).
|
30815927 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutational analyses performed following acquired ibrutinib resistance have suggested that chronic lymphocytic leukemia (CLL) progression on ibrutinib is linked to mutations in Bruton tyrosine kinase (<i>BTK</i>) and/or phospholipase Cγ2 (<i>PLCG2</i>) genes.
|
31243043 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
While the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL), current limitations include off-target toxicities and the development of resistance.
|
31028669 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The functional relevance of BTK for lymphoid malignancies is strongly supported by the observation that resistance to therapy in CLL patients treated with BTK inhibitors such as ibrutinib is often associated with mutations in genes coding for BTK or Phospholipase-C gamma (PLCɣ).
|
30700840 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that CC-292 is a specific BTK inhibitor with promising performance in combination with bendamustine in CLL.
|
30468254 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of Bruton tyrosine kinase (BTK) is a breakthrough therapy for certain B cell lymphomas and B cell chronic lymphatic leukemia.
|
31217352 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In primary chronic lymphocytic leukemia (CLL) lymphocytes, pharmacological interference with mitochondrial ATP synthesis or glucose metabolism affects BTK activity.
|
31363127 |
2019 |
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a BTK inhibitor, has demonstrated marked efficacy and tolerability in treatment-naïve, relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).
|
31638169 |
2019 |